COMMUNIQUÉS West-GlobeNewswire

-
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2025
07/08/2025 -
Nualtis Announces Strategic Partnership with OrthoNu for Innovative Orthodontic Care Products
07/08/2025 -
UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results
07/08/2025 -
Milestone Achievement for Hospital Using Catheter Precision’s VIVO System
07/08/2025 -
Annovis Completes Full Patent Transfer to Crystal Buntanetap
07/08/2025 -
Route 92 Medical Files Patent Infringement Suit Against Balt
07/08/2025 -
MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
07/08/2025 -
Stryker declares an $0.84 per share quarterly dividend
07/08/2025 -
Privia Health Reports Second Quarter 2025 Financial Results
07/08/2025 -
Dentsply Sirona Reports Second Quarter 2025 Results
07/08/2025 -
LifeStance Reports Second Quarter 2025 Results
07/08/2025 -
Enovis Announces Second Quarter 2025 Results
07/08/2025 -
DeepHealth, a RadNet Subsidiary, Receives FDA Clearance for Remote Scanning Solution, TechLive™
07/08/2025 -
Accumulus Synergy crée Accumulus Technologies pour développer sa plateforme réglementaire éprouvée et accélérer l’accès mondial aux thérapies
07/08/2025 -
IBA Notice of Half Year 2025 Results and Conference Call
07/08/2025 -
IBA : Publication des résultats du premier semestre 2025 et conférence web
07/08/2025 -
SNIPR BIOME Raises EUR 35 Million Series B Financing to Advance CRISPR-Medicines Targeting Antimicrobial Resistance
07/08/2025 -
Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information
07/08/2025 -
Valneva annonce la levée de l’arrêt temporaire de la FDA sur l’utilisation du vaccin contre le chikungunya IXCHIQ® chez les personnes âgées et une mise à jour des caractéristiques du produit
07/08/2025
Pages